|Articles|August 25, 2021

Real Chemistry and Aktana Announce New Partnership

Partnership pairs Aktana’s Contextual Intelligence Engine with Real Chemistry’s data and creative campaign.

Real Chemistry, a global health innovation company, and Aktana, a pioneer in intelligent customer engagement for the global life sciences industry, today announced a partnership that will reimagine commercial strategy, engagement and execution. Pre-built integrations between the two companies’ solutions will translate Real Chemistry’s healthcare social data points from 3 million healthcare influencers and 160,000 healthcare providers (HCPs) and claims data into dynamic, actionable insights for life sciences sales, marketing and medical teams.

Through this partnership, life sciences companies will be equipped not only to identify the right HCPs, but also to predict the right engagement timing, content, channel, and next-best actions to help HCPs learn about new treatment options and improve patient care.

Read more about the new partnership here.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.